# Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis

> **NCT02204397** · PHASE2 · COMPLETED · sponsor: **Jewish General Hospital** · enrollment: 5 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** INGAP Peptide, Ustekinumab

## Key facts

- **NCT ID:** NCT02204397
- **Lead sponsor:** Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-03-08
- **Final completion:** 2017-03-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204397, "Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02204397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*